Full-Time

Senior Scientist II

Computational Discovery Science

Confirmed live in the last 24 hours

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$140k - $190kAnnually

+ Incentive Compensation + Restricted Stock Units

Senior

Company Historically Provides H1B Sponsorship

San Francisco, CA, USA

Hybrid role; expected to work in-office some days.

Category
Computational Biology
Genomics
Public Health
Biology & Biotech
Required Skills
Python
R
SQL

You match the following Tempus's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • PhD degree in a quantitative discipline (e.g., Biostatistics/Statistical Genetics, Bioinformatics, Computational Biology, Computational Immunology, or similar) plus 2 years of experience or postdoctoral studies
  • Alternatively, a PhD in Molecular Biology or another Life Science degree combined with a very strong record of computational biology
  • Minimum 2+ years in drug development leveraging genomic and clinical/real-world data for drug discovery and development
  • Proficient in R, Python, and SQL
  • Strong understanding of cancer biology
  • Excellent written and verbal communication skills, with the ability to present complex information clearly and persuasively to diverse audiences
Responsibilities
  • Partner with our pharma clients to design, develop, and execute computational target discovery research projects leveraging the Tempus platform to advance precision medicine research programs
  • Develop and implement scientific strategies and experimental work plans, including identifying new methodologies and approaches for large clinico-genomic databases and PDOs
  • Integrate the above to prioritize target opportunities matched to biomarker and indication strategies that enhance the likelihood of developmental success
  • Evaluate clinical trial design by testing assumptions, refining eligibility criteria, and characterizing patient outcomes on standard of care
  • Develop novel biomarkers of response signatures
  • Independently execute complex translational or real-world evidence research projects integrating molecular and clinical data from Tempus’ multimodal data platform to derive real-world insights for biopharma partners
  • Expert in navigating client interactions; present scientific findings clearly and meaningfully to diverse sets of external stakeholders
  • Document, summarize, and communicate highly technical results and methods clearly to non-technical audiences
  • Author abstracts, posters, and peer-reviewed publications to illustrate the value of multimodal analysis and AI in drug discovery in coordination with our partners or internal R&D teams
  • Become an expert in our biopharma partners’ strategy, pipeline, and portfolio to proactively determine all areas that the Tempus platform could add value to the drug development process of our partners
  • Stay current with industry trends, best practices, and advancements in computational oncology research. Apply this knowledge to enhance research methodologies and improve overall research quality on the team.
Desired Qualifications
  • Strong understanding of statistical methods, molecular data, and machine learning in drug discovery with experience in integrative modeling of multi-modal clinical and omics data
  • Previous experience working with large transcriptome and NGS data sets
  • Prior consulting and/or client-facing experience is highly desirable
  • Ability to work collaboratively in a team environment
  • Thrive in a fast-paced environment and willing to shift priorities seamlessly
  • Experience with R package development
  • Strong peer-reviewed publication record
  • Experience with: Pandas, NumPy, SciPy, Scikit-learn, Jupyter Notebooks, RStudio, tidyverse, ggplot, Git, matplotlib, seaborn
  • Goal orientation, self-motivation, and drive to make a positive impact in healthcare

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where they have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Unlike many competitors, Tempus combines extensive research with practical applications in patient care and drug development. The goal of Tempus is to improve healthcare delivery and outcomes by leveraging advanced data analysis and AI.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$894.9M

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus' AI platform is connected to over 50% of US oncologists.
  • The launch of the Olivia app empowers patients with AI-driven health management.
  • Partnerships with Genialis and Artera expand Tempus' AI capabilities in oncology.

What critics are saying

  • Emerging AI healthcare startups may threaten Tempus' market share.
  • Data privacy concerns with Olivia app could lead to regulatory scrutiny.
  • Dependency on external technologies may pose integration challenges.

What makes Tempus unique

  • Tempus uses AI to analyze clinical and molecular data for precision medicine.
  • Their platform aids in personalized cancer treatment through AI-driven insights.
  • Tempus collaborates with biotech firms to enhance drug development using AI.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
ETF Daily News
Feb 15th, 2025
Apollon Wealth Management LLC Makes New $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM)

Apollon Wealth Management LLC makes new $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM).

Money Morning
Feb 14th, 2025
Nancy Pelosi's Favorite AI Stock Rising Again After 13% Surge

Tempus announced yesterday that it was collaborating with the nonprofit Institute for Follicular Lymphoma Innovation to develop treatment options for patients with the disease.

Medical Device Network
Feb 13th, 2025
Artera partners with Tempus to expand AI cancer test access

Currently connected to more than 50% of all oncologists practising in the US, Chicago-based Tempus will work with Artera on an exclusive basis to commercialise the latter's ArteraAI prostate test.

TipRanks
Feb 13th, 2025
Tempus AI enters collaboration with Institute for Follicular Lymphoma Innovation

Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation.

Hit Consultant
Jan 23rd, 2025
Tempus Ai Launches Ai-Powered Personal Health Concierge App

What You Should Know:– Tempus AI, a provider of AI-powered precision medicine launches olivia, an innovative personal health concierge app designed to revolutionize how patients manage their health information.– olivia brings together a patient’s health data from various sources, leverages AI to provide actionable insights, and empowers patients to take control of their health journey.Centralizing Health DataOlivia serves as a central hub for all of a patient’s health information. Patients can connect to over 1,000 health systems through electronic health record (EHR) integration, sync data from health devices to track daily metrics, or manually upload health records. This comprehensive data integration allows patients to access a complete and accurate picture of their health history.Actionable Insights Through AIolivia’s AI-enabled capabilities transform raw data into actionable insights. Patients can ask questions about their records, summarize their health information, and receive personalized responses based on their data. For example, a patient can ask, “Summarize my health status,” and olivia will provide a clear, concise summary of their health information.Empowering Patients to Take Control of Their HealthIn addition to centralizing data and providing actionable insights, olivia offers several other features to enhance the patient experience:Smart Profile Summary: olivia synthesizes a patient’s data into an AI-generated smart profile, detailing information such as clinical diagnoses, family history, medications, and care team.olivia synthesizes a patient’s data into an AI-generated smart profile, detailing information such as clinical diagnoses, family history, medications, and care team. AI-enabled Notetaker: olivia provides patients with written transcripts, audio files, and smart summaries of physician appointments, accessible and searchable via the app’s AI interface.olivia provides patients with written transcripts, audio files, and smart summaries of physician appointments, accessible and searchable via the app’s AI interface